At ADLM, lipoprotein(a), measles, and more
June 2026—Despite elevated Lp(a) concentration having a high population prevalence of about 20 percent, the testing rate has been low, and that is about to change.
Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.
Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, July 21, 2026, 11:00-11:30 AM CT
Roundtable presenters Nick Fingland, PhD, PMP, Senior Director, R&D Operations and Science, BD, and Chris Farnsworth, PhD, D(ABCC), Section Head of Clinical Chemistry, Professor of Pathology and Immunology, Washington University School of Medicine.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
June 2026—Despite elevated Lp(a) concentration having a high population prevalence of about 20 percent, the testing rate has been low, and that is about to change.
June 2026—Alternative revenue models for laboratories, specifically laboratory testing for functional health and other health care practices that traditionally haven’t been part of conventional medicine, came up in a May 6 online Compass Group roundtable, led by CAP TODAY publisher Bob McGonnagle.
May 2026—In the laboratory general accreditation checklist in the 2025 edition, released last December, is new emphasis on a prospective risk assessment process in the laboratory’s quality management …
April 2026—Revisions and additions to the CAP transfusion medicine accreditation checklist released last year were made to safeguard patients, donors, and the blood bank inventory.
March 2026—An international panel of experts in multiple sclerosis and cerebrospinal fluid diagnostics reached a consensus in 2023, and they recommended including the determination of intrathecal kappa free light chain synthesis in the next revision of MS diagnostic criteria as an additional tool to measure intrathecal immunoglobulin synthesis.
March 2026—More flexibility and less burden sum up the personnel requirement changes in the accreditation program checklists released in December last year. The revisions to the CAP checklists stem from changes that the Centers for Medicare and Medicaid Services announced on June 23, 2025 in response to feedback the CMS had received about what it required in the CLIA final rule implemented on Dec. 28, 2024. The announcements were in CMS memorandum QSO-25-21-CLIA (CLIA Enforcement Discretion and Clarification on Personnel Regulations) and QSO-25-10-CLIA Revised (Revisions to State Operations Manual, Appendix C–Advance Copy).
March 2026—Laboratory leaders from various health systems discussed strategies to navigate competition and ensure growth.
March 2026—A roundtable discussion focused on improving workflow efficiency in urinalysis, highlighting the potential of AI to enhance reflex testing by integrating test results with EHR data.
February 2026—The 2024 revision of the 2017 McDonald criteria for diagnosing multiple sclerosis allows the kappa-free light chain index to replace oligoclonal band detection in cerebrospinal fluid analysis.
February 2026—Washington University in St. Louis implemented a clinical decision support intervention to reduce unnecessary magnesium testing.